Roche Launches Phase 2 TARBELA-AD Trial of NLRP3 Inhibitor in Alzheimer Disease

Author profile image Aggregator
0 comments
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.

Source: NeurologyLive Published 17 Nov 2026 Imported 17 Nov 2026 Relevancy: Not reviewed

Read the article